Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

Strojek, Krzysztof; Yoon, Kun‐Ho; Hrubá, Veronika; Elze, M.; Maria Langkilde, Anna; Parikh, Shamik

doi:10.1111/j.1463-1326.2011.01434.x

Public

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

Published in Diabetes Obesity and Metabolism • Jun 15, 2011

Authors:

Krzysztof Strojek

Kun‐Ho Yoon

Veronika Hrubá

Abstract

AIMS: Progressive deterioration of glycaemic control in type 2 diabetes mellitus (T2DM) often requires treatment intensification. Dapagliflozin increases urinary glucose excretion by selective inhibition of renal sodium-glucose cotransporter 2 (SGLT2). We assessed the efficacy, safety and tolerabili...

Subject

Diabetology

Medicine

Dapagliflozin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!